Arcellx (NASDAQ:ACLX – Free Report) had its target price raised by Truist Financial from $87.00 to $136.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. ACLX has been the topic of several other reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcellx in a […]

SoundHound AI (NASDAQ:SOUN – Get Free Report) had its target price boosted by investment analysts at HC Wainwright from $7.00 to $8.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 27.59% from the stock’s previous close. […]

Onestream (NASDAQ:OS – Get Free Report) had its target price raised by equities researchers at Raymond James from $34.00 to $35.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Raymond James’ price target would indicate a potential upside of 8.23% from the stock’s previous close. […]

Steven Madden (NASDAQ:SHOO – Free Report) had its price target upped by Citigroup from $43.00 to $45.00 in a research report released on Friday,Benzinga reports. Citigroup currently has a neutral rating on the textile maker’s stock. Other equities analysts have also recently issued reports about the company. Piper Sandler reissued a “neutral” rating and set […]

Castle Biosciences (NASDAQ:CSTL – Free Report) had its price objective raised by KeyCorp from $28.00 to $36.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an overweight rating on the stock. Other equities analysts also recently issued reports about the stock. Robert W. Baird upped their price target on shares […]

VSE (NASDAQ:VSEC – Get Free Report) had its target price lifted by stock analysts at B. Riley from $120.00 to $132.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the construction company’s stock. B. Riley’s price objective suggests a potential upside of 12.05% from the company’s previous close. […]

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target hoisted by Oppenheimer from $95.00 to $105.00 in a report released on Thursday,Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock. GILD has been the subject of several other research reports. Piper Sandler boosted their price objective on shares of Gilead […]